ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Gritstone Announces Presentations during Three Upcoming Investor Conferences

December 30, 2021 GMT

EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in the following upcoming investor conferences in January.

Conference: JP Morgan 40th Annual Global Healthcare Conference
Presentation Date and Time: Thursday, January 13, 2022 at 8:15 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Conference: H.C. Wainwright BioConnect Conference 2022
Presentation Date and Time: Available beginning Monday, January 10, 2022 at 7:00 a.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

Conference: B. Riley Securities’ 2022 Virtual Oncology Conference
Presentation Date and Time: Thursday, January 27, 2022 at 1:30 p.m. ET
Presenter: Andrew Allen, M.D., Ph.D., co-founder, president, and chief executive officer

ADVERTISEMENT

Live webcasts of all presentations will be accessible via the Investors & Media section of the company’s website at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following each event.

ADVERTISEMENT

About Gritstone
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstone.com.

Gritstone Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

Investors:
George E. MacDougall
gmacdougall@gritstone.com
Tel: +1-703-509-7961